Skip to main content

Identification of genetic roots of coronary artery disease by combining stepwise genome wide association studies with transcriptomic and functional genomic investigation of relevant genetic variants

Objective

The heritability of coronary artery disease (CAD) and myocardial infarction (MI) has been unequivocally demonstrated. However, traditional technology, for example based on investigation of candidate genes, or linkage analysis, has failed to elucidate the genetic roots of the Number One killer in society. Cardiogenics will exploit the major advances in genomics to identify risk genes for CAD/MI. The investigators have established large collections of affected individuals with an exceptionally strong genetic signal and subjected these to high-density genome-wide association analyses. These and other components of a multi-step genome-wide based strategy will uncover strong candidate genes (SCG). The implications of SCGs will be tested by the integrated functional genomics programme. Specifically, we will relate variants of SCG to the transcriptomes of monocytes and coronary plaques as well as more complex human phenotypes. Moreover, SCG variants will be further characterised, by small interfering RNA technology in stem cells, at the protein level, and functionally investigated. Ultimately, our globally competitive, integrated programmes spanning from genome-wide mapping to cell biology will determine the physiological roles of genes and proteins implicated in CAD/MI genetics and thus lead to the identification of novel drugable targets.The likelihood that we will achieve our ambitious goals is greatly increased by the fact that we have brought together leading European academic groups, and received substantial financial and logistic support from major national initiatives (WTCCC in the UK and NGFN in Germany), large pan-European projects (MORGAM, BLOODOMICS, EUMORPHIA), and from Europe's premier genome centre, the WTSI. The seamless transfer of inventions to the small-and-medium-sized enterprises (EUROIMMUN and TRIUM) and the pharmaceutical sector will provide the basis of a return on the initial investment'.

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Funding Scheme

IP - Integrated Project

Coordinator

UNIVERSITÄT ZU LÜBECK
Address
Ratzeburger Allee 160
23538 Luebeck
Germany

Participants (18)

UNIVERSITY OF LEICESTER
United Kingdom
Address
University Road
Leicester
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Rue De Tolbiac 101
Paris Cedex 13
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
Address
The Old Schools, Trinity Lane
Cambridge
UNIVERSITY OF REGENSBURG
Germany
Address
Franz-josef-strauss-allee 11
93042 Regensburg
GENOME RESEARCH LIMITED
United Kingdom
Address
215 Euston Road
London
SANQUIN BLOOD SUPPLY FOUNDATION
Netherlands
Address
Plesmanlaan 125
9892 Amsterdam
GSF-FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT, GMBH
Germany
Address
Ingolstadter Landstrasse 1
Muenchen-neuherberg
JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
Germany
Address
Saarstr. 21
Mainz
UPPSALA UNIVERSITET
Sweden
Address
St Olofsgatan 10B
256 Uppsala
THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom
Address
University Road
Belfast
UNIVERSITY OF LEEDS
United Kingdom
Address
Woodhouse Lane
Leeds
ASSOCIAZIONE PER LO STUDIO DELLA TROMBOSI IN CARDIOLOGIA
Italy
Address
Piazza Golgi 1
Pavia
EUROIMMUN MEDIZINISCHE LABORDIAGNOSTICA AG
Germany
Address
Seekamp 31
Lubeck
TRIUM ANALYSIS ONLINE GMBH
Germany
Address
Hohenlindenerstr 1
Munich
TECHNISCHE UNIVERSITÄT MÜNCHEN
Germany
Address
Arcisstrasse 21
München
UNIVERSITY HOSPITAL REGENSBURG
Germany
Address
Franz-josef-strauss-allee 11
93042 Regensburg
UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
Germany
Address
Langenbeckstr. 1
Mainz
NATIONAL INSTITUTE OF HEALTH AND WELFARE
Finland
Address
Mannerheimintie 166
Helsinki